Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab.

Biologics · 2007 · PMC2721313 · PMID 19707329

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The difference in progression-free survival and overall survival did not reach statistical significance, and due to the trial design it cannot be definitively determined if treatment with the bevacizumab results in superior survival to standard therapy in the second-line setting.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.